A liquid biopsy is a non-invasive medical test used to detect and analyze various biomarkers in a person's blood, urine, or other bodily fluids. It offers valuable insights into the presence and characteristics of diseases, particularly cancer. The term "liquid" refers to the fact that the sample is obtained in liquid form, without the need for traditional tissue biopsies, which involve removing a piece of tissue from the body.

The liquid biopsy is primarily used for the early detection, monitoring, and characterization of cancer. When cancer is present in the body, it sheds certain components, such as circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), extracellular vesicles, and proteins, into the bloodstream or other body fluids. These components are known as biomarkers, and their presence and characteristics can provide valuable information about the cancer, including its type, stage, genetic mutations, and potential response to treatment.

Our next generation circulating cfRNA transcripts-based cancer liquid biopsy is a type of liquid biopsy that focuses on analyzing the messenger RNA (mRNA) molecules present in a patient's bloodstream. These mRNAs are released into the blood by various cells, including cancer cells, and can provide valuable information about gene expression and molecular changes associated with different diseases, including cancer. This technology provides a more powerful, more precise, more differentiated and earlier diagnosis.